ABIOGEN BEGINS GAD DRUG STUDY

A A

Abiogen Pharma has announced the start of a Phase II clinical trial in Vienna in patients affected by generalized anxiety disorder (GAD) with ABIO 08/01, a new anti-anxiety drug.

ABIO 08/01 is the first in a new class of non-addictive drugs, different from anxiolytic sedatives, and is being developed to treat clinical anxiety states such as panic disorder or GAD.

The pharmacological efficacy of ABIO 08-01 was studied in several animal models of anxiety and showed that the molecule was active after a single oral administration.